(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied.
Related Topics
Ovarian Cancer Research Alliance Launches Community Accelerated Research Exchange, a Global AI-Powered Ecosystem to Transform Gynecologic Cancer Research
Platform, powered by AWS, connects patients, researchers, and clinicians to accelerate breakthroughs in gynecologic cancers [NEW YORK, NY – May 8, 2026] — Ovarian Cancer Research Alliance (OCRA) today announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting … Continued
Global Ovarian Cancer Research Consortium Announces Next AI Accelerator Grant to Advance Data-Driven Discovery
On World Ovarian Cancer Day, May 8, the Global Ovarian Cancer Research Consortium announces a second $1 million USD grant along with AWS compute support to power research that aims to improve ovarian cancer survival rates On World Ovarian Cancer Day the Global Ovarian Cancer Research Consortium, of which Ovarian Cancer Research Alliance (OCRA) is … Continued
The Overview: April 2026
Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’s 2026 Notable Leader in Health Care Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and … Continued
